Description

KLOW (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg) – Pre-filled Laboratory Cartridge for In Vitro Research (80 mg / 3 ml)

Four-component synergistic research peptide complex comprising copper tripeptide (GHK-Cu), gastric pentadecapeptide (BPC-157), biomimetic thymosin  fragment (TB-500), and anti-inflammatory -MSH C-terminal tripeptide (KPV) in a pre-formulated stabilized buffered solution for in vitro research on multi-target extracellular matrix remodeling, NF-B pathway suppression, angiogenesis, and cytoprotection

Overview & Mechanism of Action (In Vitro)

The KLOW research complex is an advanced quad-peptide bioactive formulation that expands the regenerative extracellular matrix paradigm by integrating a potent anti-inflammatory modulator (KPV) for comprehensive in vitro investigations in cell biology, experimental immunology, and tissue engineering:

• Triple-Action Extracellular Matrix (ECM) Synthesis: GHK-Cu upregulates gene transcription of type I and III collagen and tropoelastin, BPC-157 accelerates fibroblast migration via the FAK-paxillin focal adhesion axis, and TB-500 coordinates structural tissue organization in vitro.
• Targeted Suppression of Inflammatory NF-B Cascades (KPV): The tripeptide KPV (Lys-Pro-Val) directly inhibits the nuclear translocation of NF-B, markedly attenuating the transcription of pro-inflammatory cytokines (IL-1$\beta$, IL-6, TNF-) in cellular models stimulated with endotoxins (LPS).
• Synergistic Angiogenesis & Microvascular Network Assembly: BPC-157 stimulates VEGFR2 phosphorylation and eNOS activation, TB-500 facilitates endothelial capillary-like tube formation through matrix metalloproteinase (MMP) regulation, and GHK-Cu upregulates basic fibroblast growth factor (bFGF) and VEGF secretion in vitro.
• Actin Cytoskeletal Dynamics & Accelerated Motility: TB-500 sequesters monomeric G-actin in a 1:1 ratio to maintain cytoskeletal plasticity, working in synergy with BPC-157 and KPV to accelerate cell migration and defect closure in monolayer scratch assays.
• Comprehensive Cytoprotection & Apoptotic Defense: Enhances endogenous superoxide dismutase (SOD) activity, suppresses caspase-3 cleavage, and shields cell cultures against oxidative, inflammatory, and ischemic insults in vitro.
• Pre-formulated Format for Precise Laboratory Dispensing: A stable liquid formulation containing all four peptides at a defined 5:1:1:1 ratio (80 mg total active peptide content / 3 ml) eliminates errors associated with separate manual reconstitution and blending steps.

Technical & Chemical Specifications

• Classification: Quad-Component Research Peptide Standard / Extracellular Matrix & Anti-Inflammatory Modulator / Research Solution (RUO)
• Product Format: Pre-filled calibrated laboratory cartridge (3 ml volume)
• Active Content per Cartridge (Total 80 mg / 3 ml):
  • GHK-Cu: 50 mg (approx. 16.67 mg/ml concentration)
  • BPC-157: 10 mg (approx. 3.33 mg/ml concentration)
  • TB-500: 10 mg (approx. 3.33 mg/ml concentration)
  • KPV: 10 mg (approx. 3.33 mg/ml concentration)
  • Total Peptide Strength: approx. 26.67 mg/ml
• Form: Sterile stabilized characteristic blue solution / Ready-to-Use (RTU)
• Solution Matrix: Sterile buffered isotonic solution for laboratory use (pH-optimized, requires no reconstitution or dilution)
• Compatibility: Compatible with standard laboratory dispensing pens and micro-dispensers for 3 ml cartridges (dispensing pen/injector is not included in the package)
• Storage Conditions: Store at 2–8 °C in a dark, refrigerated environment. Do not freeze. Maintain standard laboratory cold-chain protocols to preserve compound stability.

Scientific References & Literature

• Pickart, L., & Margolina, A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018.
• Sikiric, P., et al. Stable gastric pentadecapeptide BPC 157 in cellular systems: In vitro mechanisms of endothelial survival, VEGF upregulation, and tissue remodeling. Current Pharmaceutical Design, 2018.
• Goldstein, A. L., et al. Thymosin beta4: Actin-sequestering protein and its multifunctional role in cellular migration and tissue repair in vitro. Annals of the New York Academy of Sciences, 2012.
• Catania, A., et al. The anti-inflammatory peptide alpha-MSH and its C-terminal tripeptide KPV: In vitro inhibition of NF-kappaB activation and inflammatory signaling. Peptides, 2006.
• Land, S. C. Cellular mechanisms of KPV tripeptide in downregulating inflammatory cytokine cascades in epithelial and endothelial cell models. Biochemical Pharmacology, 2012.

Legal Disclaimer & Terms of Purchase

This product is classified and supplied strictly for laboratory, scientific, and in vitro research purposes only (Research Use Only – RUO). The stabilized peptide solution and mechanical cartridge are not drugs, medicines, anti-inflammatory therapeutics, cosmetic formulations, dietary supplements, or medical devices, and are not intended for human or veterinary consumption, oral ingestion, direct administration, injection, or diagnostic procedures.

By placing an order, the purchaser explicitly confirms that they are at least 18 years of age, possess the requisite professional qualifications and laboratory infrastructure to safely handle research substances, and are fully conversant with all relevant laboratory safety protocols. The seller assumes no liability for any use contrary to these terms.